Jung‐Min Lee - Concepedia

Author

Jung‐Min Lee

Also Known As

J. Lee, J.‐M. Lee, Jun Gi Lee, Jung-Min Lee, Jung-min Lee, Jungmin Lee, Jung‐Min Lee, Min-Hee Hong, The Korean Society of Culture and Convergence

110

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Catholic University of Korea National Institutes of Health Dana-Farber Cancer Institute Chungnam National University

About

Jung‐Min Lee is an author at National Cancer Institute specializing in medicine, ovarian cancer, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	310
2	Health Sciences	3	3	49
3	Education	1	1	20
4	Management	1	1	61
5	Nursing	1	1	20

Jung‐Min Lee

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study Jung‐Min Lee, Jayakumar R. Nair, Alexandra S. Zimmer, The Lancet Oncology MedicineGynecologyPathologyCancer TreatmentCancer Genetics	2018	210
CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells In-Young Jung, Yoon-Young Kim, Ho-Sung Yu, Cancer Research	2018	210
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget, Clinical Cancer Research	2020	209
Establishment of Blood Glucose Monitoring System Using the Internet Hyuk‐Sang Kwon, Jae‐Hyoung Cho, Hee‐Soo Kim, Diabetes Care	2004	199
The long-run impact of a traumatic experience on risk aversion Young Il Kim, Jung‐Min Lee Journal of Economic Behavior & Organization Risk CommunicationBehavioral SciencesBehavioral Decision MakingPsychosocial DeterminantRisk Management	2014	193
Long‐term effects of a structured intensive diabetes education programme (SIDEP) in patients with Type 2 diabetes mellitus—a 4‐year follow‐up study Sun-Hye Ko, K.H. Song, SooRyang Kim, Diabetic Medicine	2007	96
Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases <i>in vitro</i> toxicity of PARP inhibition by preventing Rad51 foci formation in <i>BRCA</i> wild type high-grade serous ovarian cancer Ethan Brill, Takuhei Yokoyama, Jayakumar R. Nair, Oncotarget	2017	79
Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies Carl Noble, Sapna Gangaputra, Ian Thompson, Ocular Immunology and Inflammation	2019	66
Underestimation of DCIS at MRI-Guided Vacuum-Assisted Breast Biopsy Jung‐Min Lee, Jennifer B. Kaplan, Melissa P. Murray, American Journal of Roentgenology	2007	65
A failed attempt to explain within subject variation in risk taking behavior using domain specific risk attitudes Cary Deck, Jung‐Min Lee, Javier A. Reyes, Journal of Economic Behavior & Organization Risk CommunicationBehavioral SciencesBehavioral Decision MakingSubject VariationBias	2012	61

Page 1